Conference Coverage

Interrupting oral anticoagulation in AF carries high thromboembolic cost

Publish date: November 1, 2016

 

AT THE ESC CONGRESS 2016

Pages

Recommended Reading

Andexanet controlled factor Xa inhibitor–related bleeding
MDedge Internal Medicine
VIDEO: ICDs cut mortality in younger, healthier heart failure patients
MDedge Internal Medicine
ENSURE-AF trial supports edoxaban for electrical cardioversion
MDedge Internal Medicine
Commentary: INR instability in the NOAC era
MDedge Internal Medicine
Trials offer lessons despite negative primary endpoints
MDedge Internal Medicine
Rivaroxaban linked to more bleeding compared with dabigatran in elderly patients with nonvalvular AF
MDedge Internal Medicine
FDA reaffirms rivaroxaban’s atrial fib efficacy in ROCKET AF
MDedge Internal Medicine
Beta-blockers curb death risk in patients with primary prevention ICD
MDedge Internal Medicine
Joint European atrial fibrillation guidelines break new ground
MDedge Internal Medicine
Adaptive servo ventilation cuts atrial fib burden
MDedge Internal Medicine